HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex)
Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Blade, Joan, Cavo, Michele, Rodríguez Otero, Paula, Leleu, Xavier, Hiemenz, John W., Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrian, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Harmenberg, Johan, Zavisic, Stojan, Thuresson, Sara, Öhman, Oskar, Richardson, Paul G.
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone
Richardson, Paul G., Larocca, Alessandra, Leleu, Xavier, Oriol, Albert, Paner, Agne, Rodriguez Otero, Paula, Touzeau, Cyrille, Amor, Adrián Alegre, Maisel, Christopher, Mateos, María-Victoria, Mazumder, Amitabha, Strang, Peter, Öhman, Oskar, Harmenberg, Johan, Zavisic, Stojan, Bladé, Joan
Published in BLOOD (13.11.2019)
Published in BLOOD (13.11.2019)
Get full text
Journal Article
Conference Proceeding